类固醇难治性急性移植物抗宿主病的真实世界研究：鲁索替尼单药治疗或鲁索替尼联合体外光化学疗法或体外光化学疗法单药治疗的疗效和耐受性比较 - Suppr

Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy.

作者信息

Battista Marta Lisa, Facchin Gabriele, De Martino Maria, Chiusolo Patrizia, Russo Domenico, Malagola Michele, Saraceni Francesco, Mancini Giorgia, Rambaldi Alessandro, Cavattoni Irene Maria, Lico Albana, Nozzoli Chiara, Cuoghi Angela, Ladetto Marco, Federico Vincenzo, Micò Maria Caterina, Lupo-Stanghellini Maria Teresa, Oldani Elena, Degrandi Eliana, Gallina Anna Maria, Parma Matteo, Biffi Alessandra, Fagioli Franca, Skert Cristina, Geromin Antonella, Savignano Chiara, Isola Miriam, Fanin Renato, Ciceri Fabio, Martino Massimo, Patriarca Francesca

机构信息

Hematology and SCT Unit, S. Maria della Misericordia Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

DMED University of Udine, Udine, Italy.

出版信息

Bone Marrow Transplant. 2025 Jul 26. doi: 10.1038/s41409-025-02674-3.

DOI:10.1038/s41409-025-02674-3

PMID:40715542

Abstract

摘要

相似文献

Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy.

Bone Marrow Transplant. 2025 Jul 26. doi: 10.1038/s41409-025-02674-3.

Lower incidence of chronic graft--host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft--host disease following allogeneic stem cell transplantation.

Haematologica. 2025 Jul 1;110(7):1536-1544. doi: 10.3324/haematol.2024.286824. Epub 2025 Mar 20.

Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1677-86. doi: 10.1016/j.bbmt.2014.05.017. Epub 2014 May 24.

Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population.

Leuk Res. 2024 Dec;147:107611. doi: 10.1016/j.leukres.2024.107611. Epub 2024 Oct 29.

Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.

Cochrane Database Syst Rev. 2014 Feb 25(2):CD009759. doi: 10.1002/14651858.CD009759.pub2.

Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.

Cochrane Database Syst Rev. 2015 Dec 15;2015(12):CD009759. doi: 10.1002/14651858.CD009759.pub3.

Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience.

Front Immunol. 2025 Jul 14;16:1621708. doi: 10.3389/fimmu.2025.1621708. eCollection 2025.

Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.

Cochrane Database Syst Rev. 2015 Dec 15;2015(12):CD009898. doi: 10.1002/14651858.CD009898.pub3.

Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.

Cochrane Database Syst Rev. 2014 Feb 25(2):CD009898. doi: 10.1002/14651858.CD009898.pub2.

Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in children and adolescents.

Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD009759. doi: 10.1002/14651858.CD009759.pub4.

本文引用的文献

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.

N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22.

"Best practice" for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa' Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers.

Transfusion. 2018 Jan;58(1):217-222. doi: 10.1111/trf.14400. Epub 2017 Nov 13.

Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process.

Transfusion. 2013 Oct;53(10):2340-52. doi: 10.1111/trf.12059. Epub 2013 Jan 10.

The best endpoint for acute GVHD treatment trials.

Blood. 2010 Jul 1;115(26):5412-7. doi: 10.1182/blood-2009-12-258442. Epub 2010 Apr 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献